The randomized, controlled, double-blind clinical trial included 46 patients who had three or more recurrences of CDI and had received a full course of vancomycin for their most recent acute episode. The patients were divided into two FMT groups — one that received donor stool (heterologous FMT) and the other that received their own stool (autologous FMT) via a colonoscopy.
Here are four insights:
1. A little over 90 percent of patients in the heterologous FMT group achieved clinical cure compared with 62.5 percent of those in the autologous FMT group.
2. Every patient who developed recurrent CDI after autologous FMT was free of further CDI after subsequent donor FMT.
3. There were no serious adverse events related to FMT.
4. Donor FMT restored gut bacterial community diversity and composition to resemble that of healthy donors.
More articles on healthcare quality:
Miami Beach mosquitoes now transmit Zika, new cases show
More than 2,200 people in US have Zika, CDC says
Traditional hand hygiene audits exaggerate compliance gap between nurses, physicians
